CBD Solid Dispersion Lipid Hydrophilic Excipients Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cannabidiol (CBD) has low bioavailability due to its lipophilic nature, leading to difficulty in absorption in the gastrointestinal tract and significant first-pass metabolism, resulting in limited tissue distribution and slow absorption rates in existing oral formulations.
Innovation Solution
A solid dispersion composition comprising CBD and at least two excipients, where one excipient is a lipid and another is a hydrophilic excipient, prepared using an organic solvent to create a homogeneous system without supramolecular complexes, enhancing solubility and absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CBD is formulated with high lipid content excipients to improve solubility, then bioavailability increases through chylomicron-mediated absorption, but absorption time increases and tissue distribution is limited
Solution Approach 1:
The patent changes the concentration parameter of lipid excipients from high (traditional formulations) to low (≤20% w/w), and introduces hydrophilic excipients to create a balanced excipient system. This parameter change enables CBD to be absorbed via both lymphatic and portal routes, reducing absorption time while maintaining bioavailability and improving tissue distribution.
Solution Approach 2:
The patent creates a composite excipient system combining lipid excipients (≤20% w/w) and hydrophilic excipients (≥40% w/w) in specific ratios. This composite approach allows the formulation to leverage both lymphatic absorption (for avoiding first-pass metabolism) and direct intestinal absorption (for faster onset), resolving the contradiction between bioavailability and absorption speed.
2Reliability
If CBD is formulated with high lipid content excipients to improve solubility, then bioavailability increases through chylomicron-mediated absorption, but tissue distribution becomes limited mainly to muscle and adipose tissue
Solution Approach 1:
The patent changes the lipid excipient concentration parameter to ≤20% w/w and introduces hydrophilic excipients at ≥40% w/w, creating a balanced formulation that enables CBD to distribute to both lipid-rich tissues (via chylomicrons) and aqueous environments (via direct absorption), thereby improving tissue distribution versatility while maintaining bioavailability.
Solution Approach 2:
The hydrophilic excipients act as intermediaries that facilitate CBD dissolution and absorption in the aqueous gastrointestinal environment, enabling CBD to reach both lymphatic and portal circulation routes. This intermediary role allows broader tissue distribution beyond just lipid-rich tissues.
3Ease of operation
If CBD is administered orally, then convenience of administration is improved, but first-pass metabolism reduces bioavailability to about 6%
Solution Approach 1:
The lipid excipients act as intermediaries that facilitate chylomicron-mediated lymphatic absorption of CBD, providing an alternative route that partially bypasses hepatic first-pass metabolism. The hydrophilic excipients simultaneously enable direct intestinal absorption into portal circulation. This dual-mechanism approach maintains oral administration convenience while improving bioavailability.
Solution Approach 2:
The patent segments the absorption pathway into two routes: lymphatic absorption (via chylomicrons, avoiding first-pass metabolism) and direct portal absorption (faster but subject to first-pass metabolism). By activating both pathways through the balanced excipient system, the formulation achieves higher overall bioavailability while maintaining oral convenience.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid dispersion significantly increases CBD solubility and bioavailability, leading to faster absorption and more even tissue distribution, particularly in nerve tissue, compared to traditional formulations.
Implementation Method 1
The organic solvent is allowed to evaporate from the mixture
Implementation Method 2
The organic solvent is allowed to evaporate from the mixture
Data Source
AI summary
The present invention relates to a composition comprising cannabidiol and at least two excipients, wherein at least one excipient is a lipid excipient and wherein at least one excipient is a hydrophilic excipient, and wherein the lipid excipient is present in an amount equal to or lower than 20% of the total weight of the composition; the invention also relates to the preparation process of the composition and to pharmaceutical or nutraceutical formulations containing it.